Moderna announced the first interim analysis from the Phase III study of its COVID-19 vaccine candidate, which was found to be c.95% effective in preventing symptomatic COVID-19 disease. This follows a similar announcement from Pfizer/BioNTech last week, and the caveats we mentioned at that time remain the same. AstraZeneca-Oxford University are also due to announce initial results this month. While these results are highly encouraging, we reiterate that they do not diminish the urgent need for ....
17 Nov 2020
Rude Health - finnCap Life Sciences quarterly sector note
Cambridge Nutritional Sciences PLC (CNSL:LON), 3.8 | Synairgen plc (SNG:LON), 6.7 | hVIVO plc (HVO:LON), 28.6
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rude Health - finnCap Life Sciences quarterly sector note
Cambridge Nutritional Sciences PLC (CNSL:LON), 3.8 | Synairgen plc (SNG:LON), 6.7 | hVIVO plc (HVO:LON), 28.6
- Published:
17 Nov 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
5
Moderna announced the first interim analysis from the Phase III study of its COVID-19 vaccine candidate, which was found to be c.95% effective in preventing symptomatic COVID-19 disease. This follows a similar announcement from Pfizer/BioNTech last week, and the caveats we mentioned at that time remain the same. AstraZeneca-Oxford University are also due to announce initial results this month. While these results are highly encouraging, we reiterate that they do not diminish the urgent need for ....